Our share price analysis, data and how-to-buy guides cover significant market movements in the most popular UK shares in the FTSE 100, US stocks in the DJIA, commodities, indices, and currency pairs. They are designed to help you make more informed decisions about what to invest in, what to trade, and when to execute currency transactions.


Why is Diageo’s share price falling?
Diageo’s share price (LON:DGE) has fallen by almost -6.0 over the last week on concerns about the effect of tariffs on the group’s US sales. Diageoβs share price has lost almost -6.0% over the last 5-days, however, the shares have perked up this morning, adding +1.25%. Diageo released its H1 2025 trading update recently, which


Why did the Rolls Royce share price drop today and will its rally continue?
Rolls Royce’s share price LON:RR dropped briefly today as the stock marked time ahead of its FY 2024 results and investor roadshows. Rolls Royceβs share price dropped today but soon recovered to be trade flat compared to yesterday’s close but why was there a dip at all? Well, to answer that we only need to


Legal & General share price falling on reduced margins and AUM
Legal and Generals share price LON-LGEN is sharply down over three years but has rallied near term on an improving outlook at the insurer Beauty is in the eye of the beholder they say, and we could apply the same thing to the performance of Legal and General shares. Because if we look back over


Why is Abrdn’s share price falling?
ABRDN’s share price (LON:ABDN) has rallied by +16.0% since its mid-January update, could things be improving at the hard-pressed fund manager? Fund manager Abrdn (ticker ABDN) formerly known as Aberdeen, has seen its share price fall by more than -38.0% over the last three years. However, things appear to be looking up in 2025, with


Google’s share price is so low because of missing Q4 revenues targets
Alphabet’s share price NASDAQ:GOOG fell -8.00% after hours on a revenue miss and concerns about increased capex, at Google’s parent company. Alphabet Inc the parent company of Google, reported mixed results in its Q4 2024 earnings last night. The earnings release was upbeat but it fell short of investor expectations. Alphabet posted a +12.0% year-over-year


GSK share price still low after +6% rise after bullish earnings call
GSK share price LON:GSK rallied by +5.80% after its full earnings release showed continued growth in sales and EPS alongside a share buyback. GSK or Glaxo SmithKline to use its long-form name reported its 2024 final results this morning. The drug maker has a market cap of Β£60.0 billion and though thatβs not huge by